Adequan® Canine, brand of polysulfated glycosaminoglycan (PSGAG)

INDICATIONS
Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

IMPORTANT SAFETY INFORMATION
Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated.

Caution:
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

For additional safety information, please see Full Prescribing Information at adequancanine.com.

References:
1. Adequan® Canine Package Insert, Rev. 1/19
3. Clinician’s Brief, Aug. 2013, Canine OA, DA Canapp, DVM, CCRT, CVA, DACVSMR.
5. 2016 NAVC Proceedings, Osteoarthritis in Dogs & Cats: Novel Therapeutic Advances, M Epstein, DVM, DABVP C/F, CVPP; K Kirkby Shaw, DVM, MS, PhD, DACVS, DACVSMR.

Adequan® Canine, brand of polysulfated glycosaminoglycan (PSGAG)

INDICATIONS
Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

IMPORTANT SAFETY INFORMATION
Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see Full Prescribing Information at adequancanine.com.

For more information on this product...
www.adequancanine.com • cs@americanregent.com
ARAH Team Phone: 800-458-0163
Fax: 866-597-1991
265 Broadhollow Road, Melville, NY 11747
What does Adequan® Canine offer?

Product Features

<table>
<thead>
<tr>
<th>Feature</th>
<th>Adequan® Canine®</th>
<th>Oral Joint Supplements**</th>
<th>NSAIDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Only FDA-approved disease-modifying osteoarthritis drug (DMOAD) for dogs¹</td>
<td>✔</td>
<td></td>
<td>✗</td>
</tr>
<tr>
<td>FDA-reviewed studies with proven efficacy results for treating the OA disease process in dogs¹</td>
<td>✔</td>
<td></td>
<td>✗</td>
</tr>
<tr>
<td>Approved canine formula – polysulfated with a low molecular weight, allowing for diffusion into the joint and deposition into the cartilage¹</td>
<td>✔</td>
<td></td>
<td>✗</td>
</tr>
<tr>
<td>Shown to inhibit catabolic enzymes and promote anabolic activity in the joint¹</td>
<td>✔</td>
<td></td>
<td>✗</td>
</tr>
<tr>
<td>Shown to reduce inflammation</td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Veterinary prescription only</td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Product quality assurance, consistency and manufacturing with FDA-label requirements</td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long-standing safety profile and post-approval monitoring and reporting of adverse events with FDA</td>
<td>✔</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The specific mechanism of action of Adequan® in canine joints is not known. **Not FDA-approved NSAIDs – Nonsteroidal anti-inflammatory drugs

All products have the potential for adverse events that should be considered in overall management of any disease.

1. Adequan® Canine Package Insert, Rev. 1/19.

Rethink OA / Think DMOAD

Owners want the best for their dogs and in a recent dog owner survey it confirmed 92% showed an interest when asked about a DMOAD treatment for their OA-diagnosed dog with 56% very interested.⁶ Of those with dogs in the early stage, 52% were interested and of those at a moderate stage, 60% were interested in using Adequan Canine. Unfortunately, the study also indicated 64% had never heard of the DMOAD term for treating their OA diagnosed dog. Remind owners Adequan Canine (polysulfated glycosaminoglycan) is approved to help treat the disease and not just the signs of OA. As the only DMOAD for OA treatment it empowers a dog diagnosed with OA the ability to help them manage their disease and slow the progression of osteoarthritis to enjoy everyday adventures throughout their life.

⁶. DMOAD Pet Owner Research, Kaufman Research, Inc. October 2019. (n = 385 / Dog owners with OA diagnosed dogs, +/- 4.9% at 95% level of confidence.)

Confidence

As an FDA-approved disease-modifying OA drug Adequan Canine is proven to help slow the progression of the disease. And, the earlier it is used to help maintain key cartilage components in your canine OA patients the better chance for successful results.

Invitation (neutral)

Let’s take a look at some insightful information about Adequan Canine...

It’s the customer’s decision

...so, you can see why Adequan Canine is a treatment you will want to consider for your canine patients presenting early signs of osteoarthritis to get ahead of the disease.

First, always ask if a Adequan Canine representative has been in contact recently:

Doctor, have you diagnosed any canine osteoarthritis patients recently? Are you aware of the benefits of using Adequan Canine in the early stages of the disease?

If YES, confirm and reassure the benefits.
If NO, engage and detail the primary features and benefits noted on this SoundByte.